Atrial fibrillation, or AFib, is a fast and irregular heart rhythm that, left untreated, can lead to blood clots, stroke and heart failure. It's the most common type of arrhythmia, a potentially ...

Atrial fibrillation (AFib) is the most common form of irregular heartbeat (arrhythmia). People with AFib have many treatment options, including medications and medical procedures. However ...

Atrial fibrillation occurs when action potentials fire very rapidly within the pulmonary veins or atrium in a chaotic manner. The result is a very fast atrial rate — about 400 to 600 beats per ...

AI-Guided Cardiac Ablation in combination with pulmonary vein isolation was superior to the standard of care in the treatment of Persistent ...

Background Differences in the clinical outcomes and level of risk among Asian versus non-Asian patients with atrial ...

Patients with atrial fibrillation and a moderate-to-high risk ... years with rivaroxaban (hazard ratio for 150-mg abelacimab vs. rivaroxaban, 0.38 [95% confidence interval {CI}, ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study.

Background: Several clinical factors have been studied to predict atrial fibrillation (AF ... to AF presented lower fWP (0.036 ± 0.019 vs 0.081 ± 0.029 n.u. 2, P < 0.001) and higher SampEn ...

Compared with rivaroxaban, abelacimab is associated with fewer bleeding events in patients with AF and moderate to high risk for stroke.